# US 2025/0144178 A1 · Pharmaceutical composition for cancer treatment comprising fusion protein including il-12 and anti-fap antibody and anticancer agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144178 A1
- Document ID: US20250144178A1
- Status: Published application
- Kind: A1
- Application number: 18/836,703
- Filed: 2023-02-10
- Published: 2025-05-08
- Earliest claimed: 2022-02-11
- Assignees: Kanaph Therapeutics Inc.
- Applicants: Kanaph Therapeutics Inc.
- Inventors: Dongsu Kim; Donggeon Kim; Hyunji Lee; Yujin Yoon; Youngin Lee; Dahea Lee; Jihoon Chang; Byoung Chul Lee
- Web page: https://patentgrep.com/patent/US20250144178A1

## CPC

- A61K 38/208: {IL-12}
- C07K 14/5434: {IL-12}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 14/54: Interleukins [IL]
- C07K 16/40: against enzymes
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a combined therapeutic agent of: a fusion protein comprising IL-12 or a variant thereof and an antigen-binding site that specifically binds to FAP; and an anticancer agent. The bispecific antibody exhibits an anticancer effect by IL-12 and in particular, when the anti-FAP antibody is realized in one antibody, cancer can be efficiently treated by targeting FAP expressed highly specifically in a tumor and specifically localizing IL-12 to a tumor site. When the fusion protein is administered in combination with a known anticancer agent, there is a synergistic effect on anticancer treatment.

## Claims

### Claim 1

A pharmaceutical composition, comprising
a fusion protein comprising a first monomer comprising IL-12 or a variant thereof; and a second monomer comprising an antigen binding site that specifically binds to FAP (fibroblast activation protein alpha); and
an anticancer agent.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the IL-12 or the variant thereof comprises IL-12A (p35) or a variant thereof; and IL-12B (p40) or a variant thereof.

### Claim 3 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the variant of the IL-12B (p40) comprises an amino acid sequence obtained by one or more substitutions selected from the group consisting of K258A, K260A, K263A and K264A in the amino acid sequence of SEQ ID NO: 74.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the first monomer and the second monomer form a knob-into-hole structure.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the anticancer agent is any one selected from the group consisting of chemical anticancer agent, an anticancer virus and an immune checkpoint inhibitor.

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the chemical anticancer agent is any one selected from the group consisting of alkylating agent, microtubule inhibitor, anti metabolite and topoisomerase inhibitor.

### Claim 7 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the chemical anticancer agent is any one selected from the group consisting of cyclophosphamide, cisplatin, fluorouracil, gemcitabine, camptosar, paclitaxel and adriamycin.

### Claim 8 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the anticancer virus is talimogene laherparepvec (T-VEC).

### Claim 9 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the immune checkpoint inhibitor is any one selected from the group consisting of anti-CTLA-4 antibody, anti-PD-1 antibody, anti-PD-L1 antibody, anti-TIM3 antibody, anti-TIGIT antibody and anti-LAG3 antibody.

### Claim 10 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the immune checkpoint inhibitor is any one selected from the group consisting of ipilimumab, pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab and durvalumab.

### Claim 11

(canceled)

### Claim 12

A kit, comprising
a fusion protein comprising a first monomer comprising IL-12 or a variant thereof; and a second monomer comprising an antigen binding site that specifically binds to FAP; and
an anticancer agent as active ingredients.

### Claim 13

A method for preventing or treating cancer, comprising
a step of administering a fusion protein comprising a first monomer comprising IL-12 or a variant thereof; and a second monomer comprising an antigen binding site that specifically binds to FAP or a dimer thereof; and an anticancer agent to a subject.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the IL-12 or the variant thereof comprises IL-12A (p35) or a variant thereof; and IL-12B (p40) or a variant thereof.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the variant of the IL-12B (p40) comprises an amino acid sequence obtained by one or more substitutions selected from the group consisting of K258A, K260A, K263A and K264A in the amino acid sequence of SEQ ID NO: 74.

### Claim 16 (depends on 13)

The method according to claim 13, wherein the first monomer and the second monomer form a knob-into-hole structure.

### Claim 17 (depends on 13)

The method according to claim 13, wherein the anticancer agent is any one selected from the group consisting of chemical anticancer agent, an anticancer virus and an immune checkpoint inhibitor.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the chemical anticancer agent is any one selected from the group consisting of alkylating agent, microtubule inhibitor, anti metabolite and topoisomerase inhibitor.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the chemical anticancer agent is any one selected from the group consisting of cyclophosphamide, cisplatin, fluorouracil, gemcitabine, camptosar, paclitaxel and adriamycin.

### Claim 20 (depends on 17)

The method according to claim 17, wherein the anticancer virus is talimogene laherparepvec (T-VEC).

### Claim 21 (depends on 17)

The method according to claim 17, wherein the immune checkpoint inhibitor is any one selected from the group consisting of anti-CTLA-4 antibody, anti-PD-1 antibody, anti-PD-L1 antibody, anti-TIM3 antibody, anti-TIGIT antibody and anti-LAG3 antibody.

### Claim 22 (depends on 17)

The method according to claim 17, wherein the immune checkpoint inhibitor is any one selected from the group consisting of ipilimumab, pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab and durvalumab.

### Claim 23 (depends on 13)

The method according to claim 13, wherein the cancer is any one selected from the group consisting of gastric cancer, liver cancer, lung cancer, colorectal cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, cervical cancer, thyroid cancer, laryngeal cancer, acute myeloid leukemia, brain tumor, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, melanoma, bladder cancer, esophageal cancer, head and neck cancer, skin cancer, colorectal cancer, and lymphoma.
